Solanezumab: Ph III discontinued

Lilly terminated the double-blind, placebo-controlled, international Phase III EXPEDITION-PRO trial of IV solanezumab every 4 weeks for up to 2 years to treat prodromal AD after reviewing data from the double-blind, international Phase III EXPEDITION3 trial in patients with mild dementia due to AD. The company said it did not find evidence suggesting solanezumab would confer a meaningful benefit in the prodromal population. In November, Lilly said solanezumab missed EXPEDITION3's primary endpoint and that it would not pursue regulatory submissions for solanezumab in the trial’s indication. The company reported additional data from EXPEDITION3 in December (see BioCentury, Dec. 5, 2016 & Jan. 16, 2017)...